Factors such as the
increasing R&D activities and expenditure in the life science industry,
increasing funding for proteomics research and drug discovery, and the growing
collaboration between industries and academic institutes are the key drivers of
the research antibodies market.
The Research Antibodies
Market is expected to reach USD 12.60 Billion by 2022 from
an estimated USD 9.33 Billion in 2017, at a CAGR of 6.2% during the forecast
period.
Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793
Based on technology, the
western blotting segment accounted for the largest share of the research
antibodies market. Its ability to quantify as little as 0.1 nanograms of
protein in a sample with high specificity makes it an indispensable tool in
proteomic research; this is the key factor driving market growth.
On the basis of product,
the reagents segment accounted for the largest share of the global research
antibodies market (including reagents), in 2016. This can be attributed to the
fact that a large number of reagents are used in various routine assays and
techniques.
Based on application,
the proteomics segment accounted for the largest share of the research
antibodies market. The large share of this segment is attributed to the
deployment of proteomic-based approaches in biomarker detection and cancer
profiling, increasing R&D expenditure, and availability of funds from
various organizations.
Based on end user, the
pharmaceutical & biotechnological companies segment accounted for the
largest share of the research antibodies market owing to the high uptake of
research-specific antibodies in the drug discovery and development process,
along with the increasing use of these research tools in the ever-developing
proteomics research sector.
North America accounted
for the largest share of the research antibodies market in 2016, followed by
Europe.
The major players in the
research antibodies market (including reagents) are Thermo Fisher Scientific,
Inc. (U.S.), Merck Group , Abcam plc (U.K.), Becton, Dickinson and Company
(U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.),
GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend,
Inc. (U.S.).
No comments:
Post a Comment